We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




Next-Generation Hematology Analyzer Introduced

By LabMedica International staff writers
Posted on 04 Jul 2017
Hematology is a medical specialty dedicated to studying the physiology of blood, and the cause, diagnosis, treatment, and prevention of diseases related to blood. More...
In diagnostics testing, hematology tests look at blood composition, which includes the identification and quantification of different types of blood cells.

The Alinity hq analyzer (Abbott, Abbott Park, IL, USA) for hematology is now CE Marked and available in Europe and other countries that recognize CE Mark. The analyzer is the first in the Alinity hematology series of instruments to be commercially released, and is part of the planned integrated hematology system designed to address the productivity needs of the high-volume laboratory. The Alinity hq was built from the ground up to help solve every day operational challenges and anticipated future needs for high-volume laboratories.

Some unique capabilities of the Alinity hq system include: Innovative, advanced optical technology combined with robust algorithms to handle normal and pathological samples. Design features that are intended to reduce manual steps and minimize errors, improve confidence in data and allow for uninterrupted operation and scalable, modular design to customize configurations to better serve a broad spectrum of laboratories.

As part of the Alinity family of harmonized systems, the Alinity hq analyzer has an intuitive user interface with iconography, color coding and reporting features shared by all Alinity instruments. The Alinity family also uses a common method for sample loading and reagent management, which helps laboratories simplify technician training. The Alinity portfolio includes clinical chemistry, immunoassay, blood and plasma screening, point of care, hematology and molecular diagnostics.

Luis de Luzuriaga, divisional vice president and general manager for Abbott’s hematology business, said, “The Alinity hq launch is a key milestone for Abbott’s hematology business unit. Abbott is leading the way to providing a more efficient, complete laboratory solution that no competitor in the industry can match. With the Alinity family of harmonized systems, Abbott aims to simplify diagnostics testing across laboratory disciplines and help our customers improve patient outcomes.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.